Studies On The Correlation Of The Expression Of The Epidermal Growth Factor Receptor (EGFR) In Human Glioma Cells And The Cetuximabin-vitro Drug Sensitivity

Background:The intracranial tumor is a group of disease that very harmful to human health,its fatality rate and disability rate are high. Glioma brain tumors account for about 40%, are the most common intracranial tumors. At present, the treatment of glioma is still surgical resection, supplemented by radiotherapy, chemotherapy and other comprehensive treatment, but the overall effect is still not satisfied with the high recurrence rate and poor prognosis. In recent years, progress in the treatment of malignant tumors biggest are targeting the development and use of new drugs. Cetuximab is a newly developed molecular target for anti-cancer drugs, its specific binding to the epidermal growth factor receptor(EGFR) extracellular paragraph, can effectively block the ligands EGF, TGF-αand the combination of EGFR, inhibited by body phosphorylation, thereby blocking downstream signaling pathway exert anti-tumor effects, and its specificity, side effects, compared to traditional chemotherapeutic agents have a greater advantage. In metastatic colorectal cancer, head and neck squamous cell carcinoma and non-small cell lung cancer patients to achieve a better curative effect for patients with EGFR-positive tumors benefit, is a promising new anticancer drugs. The Cetuximab used glioma reported less study EGFR in human glioma cells, and this expression and the West Rituximab vitro experimental relevance, the evaluation or estimates of the prognosis of patients with glioma, targeted to develop individualized treatment strategies, and ultimately improve the survival of glioma patients with the time and quality of life are of great significance.Object: By enzymatic digestion method of the success of glioma cell culture specimens of 18 cases.Methods:1. At first,We collected 19 cases fresh glioma specimens from Department of Neurosurgery,First Affiliated Hospital Shanxi Medical University from February 2008 to October 2008 . using enzyme digestion method to do the glioma cell culture, 16 cases are successful.After cell-climbing film, By immunocytochemical technology, We detected the expression of EGFR in each patient's glioma cell , And under the microscope at 10 will not repeat the selection of high power field (400 times) the number of selected regions recorded positive staining of tumor cells and the overall percentage of tumor cells to provide the percentage of positive cells <10% for the negative (-), 10%～25% for weakly positive (+), 25%～50% for positive (++),> 50% for the strong positive (+++)。. 2. Selected by enzymatic digestion method glioma cell culture specimens of 16 cases of success, by the pathology and immunocytochemical technology to detect protein markers Glial fibrillary acidic protein (GFAP) identified as astrocytic tumor cells, using the Cetuximab plasma peak concentration (PPC) to carry out drug sensitivity in vitro experiments, detect the sensitivity through the MTT assay , calculated the inhibition rate.3. Using statistical software to analysis the Correlation of the expression of the epidermal growth factor receptor(EGFR)in human glioma cells and the Cetuximabin-vitro drug sensitivityObjective: To investigate the correlation of the expression of the epidermal growth factor receptor(EGFR)in human glioma cells and the Cetuximab in-vitro drug sensitivityConclusion:1. The positive rate of EGFR expression at levelⅠ～ⅡandⅢ～Ⅳgroup in human glioma cells have statistically significant , with the degree of tumor malignancy increases.2. There is a difference between the Cetuximab inhibition rate at levelⅠ～ⅡandⅢ～Ⅳgroup in human glioma cells, Of gradeⅢ～Ⅳinhibition of glioma cells was higher than that ofⅠ～ⅡLevel Group of the inhibitory rate of glioma cells.3. After statistical treatment, the positive rate of EGFR expression at levelⅠ～Ⅱand the Cetuximab inhibition rate does not exist correlation, the positive rate of EGFR expression at levelⅢ～Ⅳand the Cetuximab inhibition rate exist positive correlation. with the positive rate of EGFR expression increase, the Cetuximab inhibition rate also increased.Results: 1. The positive rate of EGFR expression at levelⅠ～ⅡandⅢ～Ⅳgroup in human glioma cells were 40.0% and 81.8%, there is a difference between theⅠ～Ⅱlevel group and theⅢ～Ⅳlevel group.2. The mean±standard deviation of the Cetuximab inhibition rate at levelⅠ～Ⅱgroup was 0.07097±0.04086,it was 0.26370±0.07615 at levelⅢ～Ⅳgroup. Using t-test between two groups, t = -5.26 P <0.01. There is a difference between the Cetuximab inhibition rate at levelⅠ～ⅡandⅢ～Ⅳlevel, the Cetuximab inhibition rate atⅢ～Ⅳlevel was higher than that ofⅠ～Ⅱlevel.3. The Spearman correlation coefficient was 0.86603 between the positive rate of EGFR expression and the Cetuximab inhibition rate at levelⅠ～Ⅱ, P>0.05;it was 0.92216 between the positive rate of EGFR expression and the Cetuximab inhibition rate at levelⅢ～Ⅳ,P<0.05.Then we can say,there is no correlation between the positive rate of EGFR expression and the Cetuximab inhibition rate at levelⅠ～Ⅱ, there is positive correlation between the positive rate of EGFR expression and the Cetuximab inhibition rate at levelⅢ～Ⅳ. with the positive rate of EGFR expression increase, the Cetuximab inhibition rate also increased.